Legend Biotech’s Post

🌱 Just as the onset of spring breathes new life into the world around us, the field of radiotheranostics is revitalizing the landscape of healthcare. Radiotheranostics, a fusion of diagnostic imaging and targeted therapy using radiopharmaceuticals, represents a paradigm shift in how we approach disease management, particularly in oncology. By harnessing the power of precision medicine, radiotheranostics offers tailored solutions that promise improved patient outcomes and enhanced quality of life. Let's spring forward with optimism, determination, and a shared commitment to improving healthcare for all! 🌷 #Radiotheranostics #PrecisionMedicine #HealthcareInnovation #SpringForward #MedicalAdvancements #TransformativeHealthcare #QualityOfLife

𝐈𝐝𝐞𝐧𝐭𝐢𝐟𝐲𝐢𝐧𝐠 𝐧𝐞𝐰 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐋𝐢𝐯𝐞𝐫 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬? This rapidly growing market is fueled by rising liver cancer cases and advancements in diagnostic techniques. Our research dives deep into:  ✔️ Market size & growth projections  ✔️ Emerging trends in early detection  ✔️ Key players and competitive landscape Download our free report to gain a competitive edge! ➡️ -https://lnkd.in/di2EytAX #livercancer #diagnostics #healthcare #marketresearch

🔎 Discover the positive outcomes of BCRC-WA's groundbreaking research on Chemotherapy-Induced Alopecia (CIA). The study explored the efficacy of scalp cooling at two different temperatures, providing valuable insights into enhancing the lives of patients undergoing chemotherapy. Dive deeper into the study and explore the findings on our website: https://lnkd.in/gnMp_zAj #breastcancer #breastcancerresearch #patientimpact #scalpcooling

Precision medicine is the future of cancer treatment. By analyzing a patient's unique genetic makeup, lifestyle, and environment, doctors can develop highly targeted therapies that maximize effectiveness while minimizing side effects. This personalized approach holds immense promise for improving patient outcomes and ultimately conquering cancer. #precisionmedicine #cancertreatment #personalizedcare #healthcare #medicalscience #futureofmedicine #cancerresearch

Patient research commissioned by Sciensus last year showed that at-home chemotherapy is a well-supported concept by those who have experienced it. The study showed that 75% of patients who received their treatment in the clinic indicated that they would have liked the option to receive it at home. Additionally, patients said that at-home treatment: - Allowed them to keep living their lives - Allowed for faster access to treatment - Could be personalised to suit their preferences - Brought feelings of resilience and hope - Enabled them to develop supportive and practical relationships with their caregivers To find out more, read our white paper which compares the benefits of receiving treatment at home versus in the clinic: https://lnkd.in/eWmTweEJ #CancerCare #CancerTreatment #Chemotherapy

Explore BCMA-targeted therapies with hem-onc experts, Drs. Richter and Usmani, and elevate your practice during Myeloma Action Month 👉 https://lnkd.in/e346_56k Don’t miss this chance to transform patient outcomes in R/R multiple myeloma #MyelomaACTIONMonth #MedEd #GetYourAnswersinCME

It’s #TimeToAccelerate the use of patient-reported outcome measures in European oncology! 📢 Patient experience and feedback is paramount, and their integration into daily professional practice should be supported as much as possible. 🩺 Read ECO’s latest Action Report on how to pick up the pace in PROMs adoption in all countries. The Report’s 12 key recommendations give a route map for health systems to follow. Dive into the main key points and read the opinion of the experts involved 📖 Access the full report at https://bit.ly/3SpbVci #EUCancerManifesto

A study (DOI: 10.1097/SLE.0000000000001270) involving 58 patients with inoperable hilar cholangiocarcinoma indicates that unilateral radioactive stents not only provide longer stent patency (202 vs. 119 days) and overall survival (229 vs. 122 days) but also show comparable rates of stent restenosis with bilateral normal stents (19.3% vs. 9.3%). These findings could guide clinical decision-making for palliative care, suggesting a potential preference for unilateral radioactive stent placement. Continued research is necessary to confirm these outcomes and establish best practices. #MedicalResearch #OncologyInnovation #PalliativeCare #RadiationTherapy #SurvivalStatistics

Life sciences companies want to connect with community oncology practices to help physicians make the best treatment decisions. One way they are doing so is by working with Ontada, which offers precision education and digital engagement through technology. Learn more in this short video featuring C. Lyn Fitzgerald. #CommunityOncology #PointOfCare

As part of our commitment to advancing patient-centered care, DIA is launching a #tolerability research project. This initiative aims to establish a standard definition of #patienttolerability in multiple solid and liquid tumor cancers, focusing on patient-reported outcomes that reflect real-world experiences and preferences. This study also aspires to develop guidelines on how to use this data to inform #clinicaltrial design, provider and patient decision-making, and more. Join us in this crucial effort to deepen our understanding of patient tolerability and ultimately improve patient outcomes worldwide. Learn more about the study’s objectives by emailing Radha.Goolabsingh@diaglobal.org. #Healthcare #LifeSciences